AT&T Inc. vs 10X Genomics Inc — how do they compare? AT&T Inc. trades at $22.3 (market cap $152.52B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: AT&T Inc. is far larger — about 27.8× 10X Genomics Inc's market cap, and AT&T Inc. pays a 5.06% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| T | TXG | |
|---|---|---|
Market Cap | $152.52B | $5.48B |
Sector | Media | Health |
52-Week High | $29.62 | $45.80 |
52-Week Low | $20.49 | $11.34 |
Enterprise Value | $297.87B | $5.02B |
Dividend Yield | 5.06% | — |
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $22.26, up 2.13% with a bullish technical signal despite mixed moving averages. The stock shows strong fundamentals with a low P/E of 7.39, robust profitability margins (net margin 16.94%), and consistent earnings beats in recent quarters. Recent cash flow improvement to $15.12B in 2025 and declining debt-to-asset ratio to 32.59% in 2024 signal financial health. The company faces competitive pressures in telecom but benefits from fiber expansion and stable wireless pricing.
Outlook remains positive with analyst consensus target of $25.61 offering 15% upside. Key opportunities include dividend yield support and fiber growth, while risks involve intense telecom competition and potential earnings volatility. Wall Street sentiment is cautiously optimistic with 41% buy ratings, though technical indicators show some overbought conditions near-term.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →